Cargando…

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma

Two tyrosine kinase inhibitors, lenvatinib and sorafenib, are available systemic therapies for patients with metastatic differentiated thyroid carcinoma. However, the treatment options for carcinoma refractory to both lenvatinib and sorafenib are limited. Here, we present a case of metastatic papill...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takinami, Masaki, Yokota, Tomoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265699/ https://www.ncbi.nlm.nih.gov/pubmed/32518548 http://dx.doi.org/10.1159/000507344

Ejemplares similares

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
por: Terashima, Yuto, et al.
Publicado: (2022)

Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma
por: Uchida‐Kobayashi, Sawako, et al.
Publicado: (2022)

Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
por: Werner, R. A., et al.
Publicado: (2016)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

MON-453 Dramatic Clinical Response to Lenvatinib in a Pediatric Patient with Advanced Metastatic Papillary Thyroid Carcinoma
por: Dujovne, Noelia Vanesa, et al.
Publicado: (2020)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib
por: Tang, Ping, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report
por: Tsuboi, Mitsuhiro, et al.
Publicado: (2017)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
por: Roque, João, et al.
Publicado: (2023)

Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report
por: Yang, Che Hseuh, et al.
Publicado: (2020)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
por: Fleeman, Nigel, et al.
Publicado: (2019)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer
por: Nakamura, Hajime, et al.
Publicado: (2020)

Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020)

Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2023)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Lenvatinib-Induced Destructive Thyroiditis in a Patient With Hepatocellular Carcinoma
por: Pandya, Anjani, et al.
Publicado: (2021)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
por: Tateai, Yoshikazu, et al.
Publicado: (2023)

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2022)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Lenvatinib in the Treatment of Differentiated Thyroid Cancer and Advanced Renal Cell Carcinoma
por: Patel, Urvi J., et al.
Publicado: (2017)

Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
por: Huang, Dongmei, et al.
Publicado: (2022)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
por: Jiang, He-Jiun, et al.
Publicado: (2021)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report
por: Tori, Masayuki, et al.
Publicado: (2018)

Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report
por: Imai, Tsuneo, et al.
Publicado: (2022)

Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report
por: Buenaventura, Daisy Carolina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rpf4un8gbstl7sjseki4iqcp7q